DK 4-10
Alternative Names: DK4-10; Next-generation cytokine therapyLatest Information Update: 23 Mar 2023
At a glance
- Originator Deka Biosciences
- Class Anti-inflammatories; Antipsoriatics; Antiseptics; Cytokines; Drug conjugates; Immunoconjugates; Immunoglobulin Fv fragments; Immunotherapies; Skin disorder therapies
- Mechanism of Action Cytotoxic T lymphocyte inhibitors; Monocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Sepsis
- Discontinued Crohn's disease
Most Recent Events
- 23 Mar 2023 Discontinued - Preclinical for Crohn's disease in USA (Parenteral) before March 2023 (Deka Biosciences pipeline, March 2023)
- 23 Mar 2023 Preclinical trials in Inflammatory bowel diseases in USA (Parenteral) (Deka Biosciences pipeline, March 2023)
- 14 Feb 2022 Preclinical trials in Crohn's disease in USA (Parenteral) (Deka Biosciences pipeline, February 2022)